Bio On is trying to put the stock market disasters of the last few weeks behind it. After the 30% loss last week (-71% in one month), the share of the Bologna-based company is stuck in the volatility auction with a rise of 10,9% 6,50 euros.
The company reaffirmed again both lcorrectness of the data indicated in the 2018 financial statements published 2 weeks ago, and what was declared in their statements to the market. The clarification came following a complaint filed by the Quintessential fund with the Milan prosecutor's office. “The company reiterates the absolute correctness of one's work, which will be demonstrated in all the competent fora", reads the note from Bio-On which then attacks the US fund which has been targeting it for months, defining Quintessential's claims "false and misleading" which, according to the bioplasty would haveand a “speculative interest in the fall in the share price”.
Going into detail, Bio-On reiterated that "the 2018 financial statements have been prepared in compliance with all legal provisions, certified by the auditing firm Ernst & Young and subsequently validated, in relation to the passages disputed by QCM in the report released last July, by two renowned experts” whose opinion “completely disproves” Quintessential's claims. Furthermore, Bio-On reiterates that it has "always carried out communications based on the utmost scruple, announcing only effectively concluded agreements" and, in cases of postponement of the terms of the agreements, that it has "always diligently provided to inform the market through the documentation filed accompanying the balance sheets"
